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Background: Sevoflurane is generally the preferred anesthetic agent for general anesthesia
in pediatric patients, due to its rapid induction and recovery characteristics. However, it has
been recognized that a major complication is emergence agitation when awakening from
general anesthesia. The aim of this study was to evaluate the occurrence rate of emergence
agitation in the operating room and postoperative recovery area following intraoperative
administration of midazolam to pediatric patients under general anesthesia.
Patients and methods: One hundred and twenty pediatric patients undergoing dental treat-
ment under sevoflurane anesthesia were enrolled in this study. The patients were divided into
three groups (n=40 each in the 0.1 mg/kg midazolam, 0.05 mg/kg midazolam, and control with
saline groups). Midazolam or saline was injected intravenously approximately 30minutes before
the end of the dental treatment. We used the Richmond Agitation and Sedation Scale (RASS) to
assess the level of sedation and drowsiness at emergence phase in the operating room. We also
used the Pediatric Anesthesia Emergence Delirium Scale (PAED) to assess the level of agitation
and delirium at the full recovery phase from anesthesia in the recovery area.
Results: At the emergence phase, the incidence of emergence agitation in the 0.1 mg/kg
midazolam group was significantly lower than in the other groups (p=0.0010). At the
recovery phase, there was no significant difference among the three groups. The odds ratio
between PAED score and RASS score was 4.0 using logistic regression analysis. The odds
ratio between PAED score and Disability was 2.5.
Conclusion: Administration of a single dose of 0.1 mg/kg midazolam dose significantly
decreases the incidence of severe emergence agitation at the emergence after sevoflurane
anesthesia, but not at the recovery phase. Furthermore, the evaluation of sedative and
agitation condition using RASS score at emergence from anesthesia is useful to predict
occurrence of agitation in the recovery phase.
Keywords: emergence agitation, sevoflurane anesthesia, pediatric patients, extreme non-
cooperation against dental treatment
Introduction
Sevoflurane is generally the preferred anesthetic agent for induction and mainte-
nance of general anesthesia in pediatric patients, including patients with extreme
non-cooperation against dental treatment and procedure, due to its rapid induction
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and recovery characteristics. However, it has been recog-
nized that one of the major complications after sevoflurane
anesthesia in pediatric patients is emergence agitation
when awakening from general anesthesia, with the
reported incidence ranging between 10% and 80%.
Emergence agitation is recognized as a major risk factor
for significant complications, such as anxiety, eating and
sleeping disorders, and enuresis, along with persistent
secondary alteration of emotional and cognitive
development.1 Furthermore, the prolonged postoperative
severe agitation might be another major complication for
safety management of these patients. These have negative
implications from a hospital management point of view,
and also cause a decline in patient satisfaction and that of
their families due to the potential for self-injury and other
injurious behaviors, and are a burden on nursing staff.
Several different kinds of drugs are used to prevent
emergence agitation from sevoflurane anesthesia in pedia-
tric patients in the operating room, such as non-opioid
analgesics, opioids,2 benzodiazepines,3 intravenous
anesthetics,4 α2 agonists,
5 and use of short acting midazo-
lam. Kulka et al6 previously described the efficacy of
a single dose of midazolam (0.1 mg/kg intravenously)
given at the end of the procedure for reducing mild emer-
gence agitation in pediatric patients aged 2–7 years under-
going minor ambulatory surgery, but stated that it was
ineffective in cases with severe emergence agitation.
Previously, Kim et al7 also revealed that a smaller dose
of midazolam (0.05 mg/kg) administered just before the
end of surgery had no effect on the incidence of severe
emergence agitation requiring pharmacologic treatment.
On the other hand, most recently, Cho et al8 found that
a lower dose (0.03 mg/kg) of midazolam could suppress
emergence agitation with minimal prolongation of the
emergence time. However, this dose also had no effect
on severe agitation at emergence from general anesthesia.
In the management of general anesthesia for dental
treatment in pediatric patients, who represent an extremely
uncooperative population due to extreme dental fear and
the excessive need for treatment,9,10 we frequently observe
a high incidence of severe agitation leading to a potentially
disruptive and dangerous situation, such as self-harm and
delirium in both operating room and recovery area.
Therefore, it is important to prevent severe emergence
agitation in pediatric patients with extreme non-
cooperation against dental treatment as part of safe
anesthesia management in both operating room and recov-
ery area during perioperative phase.
We hypothesized that a single higher dose of 0.1 mg/kg
midazolam 30 minutes before the completion of treatment
would be needed to reduce severe agitation at both the
emergence phase from general anesthesia and at the recov-
ery phase in award. The aim of this study is to evaluate the
occurrence rate of emergence agitation and the level of
sedation or agitation at two different phases after sevoflur-
ane anesthesia following intraoperative administration of
midazolam to pediatric patients who underwent dental
treatment under general anesthesia.
Materials and methods
This study was designed as a randomized, double-blind
study to examine our hypothesis, and was performed with
the approval of the Ethics Committee of Nagasaki
University Hospital. We have confirmed that this study
was conducted in accordance with the Declaration of
Helsinki. After institutional review board approval and
written informed consent from the patients’ parents, 120
patients aged less than 12 years, American Society of
Anesthesiologists physical status I or II, and scheduled to
undergo dental treatment under general anesthesia were
enrolled. Additionally, to investigate the effect of the mid-
azolam dose on emergence agitation, patients were ran-
domly divided into three groups. Pediatric patients, who
represent an extremely uncooperative population due to
extreme dental fear and the excessive need for treatment,
were included in this study. Several attempts had been
made to treat these patients in ordinary circumstances
awake, but they failed to accept any procedure.
Exclusion criteria included cerebral palsy and neurological
disorders.
The children were made to fast for 8 hours, except
a small amount of clear fluid 2 hours before anesthesia.
No sedative premedication was administered prior to
anesthesia induction because they refuse to have any addi-
tional oral medication. After application of an electrocar-
diogram, pulse oximetry and noninvasive arterial blood
pressure monitors, inhalational anesthesia induction was
performed with sevoflurane. After achieving an adequate
depth of anesthesia, an intravenous line was inserted on
the dorsum of the hand. Then, 0.6 mg/kg rocuronium was
administered to facilitate tracheal intubation and controlled
ventilation during surgery. Anesthesia was maintained
with 2% sevoflurane in 40% oxygen and a remifentanil
infusion at the rate of 0.2 μg/kg/hour. Standard monitoring
included electrocardiogram, blood pressure, pulse oxime-
try, capnography, temperature, and end-tidal anesthetic gas
Kawai et al Dovepress
submit your manuscript | www.dovepress.com
DovePress





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
measurements. Ventilation was controlled to maintain end-
tidal CO2 at 35±4 mmHg. As required for pain after tooth
extraction cases or root canal treatment in 90 patients
(75%), an adequate doses of suppository acetaminophen
(10 mg/kg) was used during surgery to prevent postopera-
tive pain. Approximately 30 minutes before the comple-
tion of treatment, according to the estimation of
completion time, patients in the midazolam group received
0.1 mg/kg or 0.05 mg/kg midazolam intravenously,
depending on the group they were allotted to, while
patients in the saline group received the same volume of
2 ml of saline. At the completion of treatment, sevoflurane
was discontinued and the endotracheal tube was removed
when the child resumed adequate spontaneous breathing,
associated with a normal range of minutes volume and
End-tidal CO2. Then, when the patients were hemodyna-
mically stable and free of pain and vomiting, they were
discharged from the operating room and moved into the
recovery area within 15–20 minutes. We compared the
incidence and severity of emergence agitation, as well as
emergence time from discontinuation of sevoflurane to
extubation and discharge times from the operating room,
in the two groups of children receiving a single dose of
midazolam 30 minutes before the completion of treatment
versus the third group of children receiving saline.
Assessment of agitation and sedation level
Of the many scales that have been proposed to evaluate
the incidence and severity of emergence agitation or
sedation, we used the two different purpose of evaluat-
ing scale, PAED4,11 and RASS,12,13 which classifies
agitation, sedation and delirium following general
anesthesia.
At the emergence phase just after an extubation after
sevoflurane aesthesia in the operating room, RASS was
used for evaluation of level of agitation and sedation
because the patients might still be drowsy due to the
influence of sevoflurane anesthesia (Table 1). The RASS
is a single tool that is intuitive, easy to use, and includes
both agitation and sedation. It is a valid scale for assessing
the responsiveness level of critically ill children. The
patients were divided into two categories based on agita-
tion and sedation levels: non-agitated condition (RASS
score: -5–0) and agitated condition (RASS score: 1–4).
At the time of emergence from anesthesia, agitation was
assessed immediately after removal of the endotracheal
tube by nurses who were unaware of the child’s group
assignment.
At the full recovery phase in the recovery area within 15
minutes, the Pediatric Anesthesia Emergence Delirium Scale
(PAED) was used for evaluation of agitation and delirium in
recovery phase because the patients might be clear enough to
be assessed using criteria by a nurse (Table 2). PAED was the
most reliable evaluating scale for agitation and delirium in
pediatric patients after recovery from anesthesia, as found by
Sikich and Lerman11.
For safe anesthetic practice, the anesthesiologists who
administered midazolam were aware of the dose, but they
did not share this information with the investigator who
Table 1 The description of Richmond Agitation-Sedation Scales
(RASS)
Score Term Description




Pulls on or removes tube(s) or catheter(s)
or has aggressive behavior toward staff
+2 Agitated Frequent nonpurposeful movement or
patient-ventillator dyssynchrony
+1 Restless Anxious or apprehensive, but movements
not aggressive or vigorous
0 Alert and
calm
−1 Drowsy Not fully alert, but has sustained awakening,
with eye contact, to voice
−2 Light
sedation
Briefly awakens with eye contact to voice
−3 Moderate
sedation
Any movement to voice
−4 Deep
sedation
No response to voice, but any movement
to physical stimulation
−5 Unarousable No response to voice or physical
stimulation
Table 2 The description of Pediatric Anesthesia Emergence
Delirium Scale (PAED)
1. The child makes eye contact with the caregiver.
2. The child's actions are purposeful.
3. The child is aware of his/her surroundings.
4. The child is restless.
5. The child is inconsolable.
Items 1, 2, and 3 are reversed scored as follows: 4 = not at all, 3 = just a little, 2 = quite a
bit, 1 = very much, 0 = extremely. Items 4 and 5 are scored as follows: 0 = not at all, 1 =
just a little, 2 = quite a bit, 3 = very much, 4 = extremely. The scores of each item were
summed to obtain a total Pediatric Anesthesia Emergence Delirium (PAED) scale score.
The degree pf emergence delirium increased directly with the total score.
Notes: Reproduced with permission from Sikich N, Lerman J, Development and
psychometric evaluation of thepediatric anesthesia emergence delirium scale,
Anesthesiology, 2004;100(5):1138–1145. Available from: http://anesthesiology.pubs.
asahq.org/article.aspx?articleid=1942731.11
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This study was powered on the basis of preliminary results
showing 50% incidence of emergence agitation in the con-
trol group. A sample size of 39 in each group was calculated
as being required to detect a decrease in the incidence of
agitation to 15% with α=0.05 and β=0.2. All statistical
analyses were performed using Prism version 5.0
(Graphpad Software, Inc., San Diego, CA, USA).
Demographic data, such as age, weight, and height, and
surgical duration were compared using the Kruskal–Wallis
test or one-way analysis of variance among the three groups.
The occurrence rate of emergence agitation and sedation
was based on the score level 1<RASS<4, defined as “agi-
tated condition”, and the sedative symptom based on the
score level -5<RASS<0, defined as “non-agitated condi-
tion”. The occurrence rate of emergence agitation and delir-
ium was based on the score level 1<PAED<9, defined as
“lower level of agitation”, and the severe level of agitation
and delirium based on the score level 10<RASS<20, defined
as “severe agitated condition”. According to the indication
by Sikich and Lerman11 that a PAED with greater than 10
should be regarded as the cut-off criteria for emergence
agitation from anesthesia, we categorized 10<RASS<20 as
“severe agitated condition”.
Categorical variables, such as the incidence of emer-
gence agitation, are reported as numbers and percentages;
these variables were compared among groups using the chi-
square test and logistic regression analysis, as appropriate.
The multivariable logistic regression analysis for occurrence
rate of agitation assessed by PAED at recovery phase with
Multiple imputations was performed using JAP Pro14 soft-
ware. In order to estimate the odds ratio between PAED
score and RASS score, the existence of disability, age,
gender, weight, and anesthesia time were analyzed.
A p-value<0.05 was considered to be significant.
Results
One hundred and twenty children were enrolled in the
study (n=40 each in the 0.1 mg/kg midazolam, 0.05 mg/
kg midazolam, and control groups). The demographic and
perioperative clinical data of patients in the three groups
are shown in Table 3. The mean age of the children in the
three groups was comparable. There were no significant
differences among the three groups in terms of periopera-
tive clinical data. The characteristics of subjects in each
group divided according to the suspected and/or the defi-
nitive diagnosis of disability are shown in Table 4.
At the emergence phase just after an extubation after
sevoflurane aesthesia in the operating room, emergence
agitation occurred in 21 cases (52.5%) in the 0.05 mg/kg
midazolam group, 15 cases (37.5%) in the 0.1 mg/kg
midazolam group, and 31 cases (77.5%) in the control
group. The incidence of emergence agitation in the
0.1 mg/kg group was significantly lower than in the other
groups (P=0.0010). In the 0.1 mg/kg midazolam group, the
estimated emergence time for successful extubation was
significantly longer than in the control group (P=0.020).
However, there was no significant difference between
emergence times in the 0.1 and 0.05 mg/kg groups.
At the full recovery phase in the recovery area
within 15 minutess, postoperative agitation and delir-
ium were assessed by PAED in 10 cases in the
0.05 mg/kg midazolam group, 15 cases in the
0.1 mg/kg midazolam group, and 14 cases in the con-
trol group. There was no significant difference among
the three groups (Table 5). Three patients claimed
slight postoperative pain in spite of an injection of
acetaminophen, and two patients expressed slight
Table 3 The demographic and perioperative clinical data of patients in the three groups. The mean age of the children in the three
groups was comparable. There were no significant differences among the three groups in terms of perioperative clinical data
Midazolam 0.1 mg/kg (n=40) Midazolam 0.05 mg/kg (n=40) Saline (n=40) p-value
Age (year) 6.2±2.0 6.1±2.4 5.9±1.8 0.85
Gender (M/F) 22/18 27/13 30/10
Height (cm) 115.0±13.8 112.7±15.1 112.8±12.4 0.71
Weight (kg) 20.1±5.7 20.0±8.0 20.3±6.7 0.99
Duration of treatment (min) 155.1±95.8 170.8±106.3 131.2±93.7 0.2
Duration of anesthesia (min) 218.8±90.2 231.1±101.6 185.3±91.6 0.09
Note: The data are presented as mean±SD.
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pain without having acetaminophen. There was no case
of sustained severe agitation that should be treated
with additional sedative drug in eithier emergence
phase or recovery phase.
The odds ratio between PAED score and RASS
score was 4.0 (p=0.0020) using logistic regression ana-
lysis (Table 6). The odds ratio between PAED score
and Disability was 2.5 (p=0.0290). The odds ratio
between PAED score and sex was 1.3 (p=0.49). The
odds ratio between PAED score and postoperative pain
was 1.9 (p=0.55). The ROC analysis to test predict-
ability of the occurrence rate of agitation at emergence
from anesthesia (1<RASS<4) and the occurrence rate
of agitation at recovery phase in award (10<PAED<20)
was 0.77 sensitivity and 0.54 specificity.
Discussion
The data in our study indicate that administration of
a single dose of 0.1 mg/kg midazolam 30 minutes before
the completion of treatment in pediatric patients with
extreme non-cooperation significantly decreases the inci-
dence of severe emergence agitation just after anesthesia,
but not in the recovery phase. Furthermore, the odds ratio
of 4.0 between PAED score and RASS score and the odds
ratio of 2.5 between PAED score and Disability may
indicate that the evaluation of sedative condition using
RASS score of Disability pediatric patients at emergence
from anesthesia might be useful methods to predict an
occurrence of agitation in the recovery phase.
Effects of midazolam and other drugs on
agitation
Several investigators have reported that intravenous injection
of benzodiazepines (0.05–0.1 mg/kg midazolam) as anxioly-
tic drugs is effective for the drug treatment of emergence
agitation.7,8,14 Cohen et al14 suggested that 0.1 mg/kg of
midazolam given intravenously at the induction of anesthesia
did not alter the incidence of emergence agitation, but it
caused a delay in emergence time and recovery in pediatric
patients undergoing adenotonsillectomy. Kim et al7 revealed
that intravenous administration of 0.05 mg/kg midazolam
just before the end of surgery is effective in reducing emer-
gence agitation, although it delays emergence time from
sevoflurane anesthesia. Most recently, Cho et al8 suggested
that a lower dose (0.03 mg/kg) of midazolam just before the
end of surgery could suppress emergence agitation with
minimal disturbance of the emergence time. However, this
Table 4 The characteristics of subjects in each group divided
according to disability. Disability patients with a definitive diag-
nosis include 16 autistic spectrum disorders (ASD), two atten-
tion-deficit hyperactivity disorder (ADHD) and 10 mental
retardation (MR). The pediatric patients with suspected diagnosis


















Table 5 The occurrence rate of agitation and sedation at emergence from anesthesia estimated by RASS score (1<RASS score<4) in
each group. 0.05 mg/kg midazolam group vs control: P=0.5146, 0.1 mg/kg midazolam group vs control: P=0.0040. The occurrence rate
of severe agitation and delirium at the recovery phase in award within 15 minutes estimated by PAED sacle (10<PAED<20) in each
group is shown. 0.05 mg/kg midazolam group vs control: P=0.2177, 0.1 mg/kg midazolam group vs control: P=0.3951. Because the data
of occurrence rate of agitation were analyzed using non-parametric, categorical variables, such as the incidence of emergence
agitation, are reported as numbers and percentages; these variables were compared among groups using the chi-square test and
logistic regression analysis, as appropriate. A p-value<0.05 was considered to be significant. The data of emergence time (minutes)








The occurrence rate of agitation at emergence from anesthesia
(1<RASS<4)
15 (37.5%) 21 (52.5%) 31 (77.5%) 0.0010　
The occurrence rate of agitation at recovery phase in award
within 15 minutes (10<PAED<20)
15 (37.5%) 10 (25.0%) 14(35.0%) NS
Emergence time (min) 17.9±6.8 16.1±6.8 13.5±6.9 0.02
Abbreviations: PAED, Pediatric Anesthesia Emergence Delirium Scale; RASS, Richmond Agitation and Sedation Scale.
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dose of midazolam also had no effect on severe agitation at
the emergence from general anesthesia. Furthermore, they
excluded patients with excessively uncooperative behaviors,
developmental delay, and neurological illness. In the present
study, we observed significant prolongation (4.5 minutes
longer than the control group) of emergence time, including
the time required to perform extubation. Therefore, we spec-
ulate that a 0.1 mg/kgmidazolam dose injected intravenously
just before the end of surgery might be adequate for reducing
severe emergence agitation in pediatric patients after sevo-
flurane anesthesia, although this dose may cause delayed
emergence compared to the control group, which is, how-
ever, a negligible level of prolongation in clinical situations.
It should be noted that a single dose of 0.1 mg/kg
midazolam could prevent severe emergence agitation
immediately after sevoflurane anesthesia. However, this
dose of midazolam could not prevent prolonged agitation
in the recovery area. We speculate that this might indicate
either the feature of a short acting effect of midazolam or
the occurrence of side-effects of midazolam, such as the
paradoxical response to midazolam, including symptoms
of agitation, confusion, delirium, and inconsolable hys-
teria. Midazolam has a short elimination half-life, with
approximately 0.4 hours Tmax as compared to other ben-
zodiazepines, due to its rapid metabolism.15 The response
varies from individual to individual, depending on the
patient’s age, susceptibility to midazolam, general condi-
tion, and drug interactions, and hence its effect may be
prolonged. However, we believe that by setting the timing
of administration at 30 minutes before the end of treat-
ment, these variables were not likely to have affected the
study results. It should also be noted that there may be an
influence of the paradoxical response to midazolam. As
has been previously described, the paradoxical response to
midazolam includes symptoms such as violent anger,
aggression, paroxysmal excitement, and assault, and may
occur in very young pediatric patients.16–18 Since the
anxiolytic effect of midazolam depends on the dosage
and the patient’s background characteristics, it is necessary
to consider that the administration of midazolam may
conversely cause excitation. Taken together, we speculate
that the strategy of use of midazolam for reduction of
emergence agitation depends on the preoperative predic-
tion of emergence agitation based on the severity of unco-
operativeness. Furthermore, we believe that other long-
lasting sedative drugs with no major influence on upper
airway patency, such as dexmedetomidine, should also be
considered to prevent severe agitation both in the operat-
ing room and recovery area, as previously suggested.5
Recently, Keles et al19,20 suggested that administration of
oral dexmedetomidine premedication may reduce post-
operative agitation and delirium in patients undergoing
dental procedures. Tsiotou et al21 also clearly revealed
that dexmedetomidine 1 mcg/kg reduces the incidence
and severity of emergence agitation after 20 and 30
minutes in post-anesthesia care unit in tonsillectomy with
Propofol anesthesia. Therefore, further studies are needed
to test effective and safe methods to reduce agitation
during the perioperative period.
It is known that, in pediatric patients receiving sevo-
flurane for induction and maintenance of anesthesia,
administration of a single dose of propofol 30 minutes
before the completion of treatment decreases the incidence
of emergence agitation without delaying emergence from
anesthesia or discharge from the operating room.4
Compared with propofol administration, benzodiazepines
have a longer effect time. A previous report showed that
premedication with benzodiazepines is effective for seda-
tion before surgery, but not for emergence agitation at
arousal from sevoflurane anesthesia. Kulka et al6 pub-
lished a study in German describing a single dose techni-
que for children aged 2–7 years undergoing minor
ambulatory surgery, involving administration of 0.1 mg/
kg midazolam intravenously at the end of the procedure.
They reported this technique as being effective in the
reduction of mild emergence agitation, but ineffective in
severe cases. According to Cho et al,8 intravenous admin-
istration of 0.03 mg/kg of midazolam just before the end
of surgery reduces emergence agitation without delaying
emergence in children undergoing strabismus surgery
under sevoflurane anesthesia. Since previous studies have
Table 6 Multivariable logistic regression analysis for PAED at











Sex: male versus female 1.3 0.49 0.6–2.9
Postoperative pain: yes versus
no
1.9 0.55 0.2–18.3
Abbreviations: PAED, Pediatric Anesthesia Emergence Delirium Scale; RASS,
Richmond Agitation and Sedation Scale.
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been performed to test emergence agitation in healthy
children, which have reported different outcomes com-
pared to the results of the present study due to the severity
of agitation, we conclude that higher doses of midazolam
0.1 mg/kg might be effective in preventing severe emer-
gence agitation after sevoflurane anesthesia in pediatric
patients with extreme non-cooperation, but not in the
recovery phase.
Another method of minimizing emergence agitation
following general anesthesia is use of propofol instead
of sevoflurane as the maintenance agent. It is well
recognized that use of propofol for anesthesia mainte-
nance after induction with sevoflurane is a valuable
anesthetic management strategy to prevent emergence
agitation in pediatric patients.22 Recently, Kocaturk and
Keles23 recommended performance of pediatric dental
procedures under total intravenous anesthesia with pro-
pofol plus remifentanil because of the resultant com-
fortable postoperative period due to less emergence
delirium. Therefore, combination of sevoflurane induc-
tion with total intravenous anesthesia maintenance
might be an alternative method to reduce emergence
agitation in dentally disabled patients who refuse intra-
venous access.
Prediction of agitation in perioperative
phase
In this study, we used the RASS to evaluate the level of
agitation and sedation at emergence from anesthesia12,13,24
and used PAED to evaluate agitation and delirium at the full
recovery phase from anesthesia in the recovery area. Previous
studies to test the effect of midazolam on emergence agitation
have used a delirium scale of PAED,7,8 which is appropriate
for evaluation of postoperative delirium in pediatric patients in
theward and recovery area.7,25 The reasonwhywe selected the
RASS as an evaluation method is that this scale can assess
overall levels of responsiveness under remaining influence of
sevoflurane anesthesia, which facilitates the reduction of
symptoms of severe emergence agitation. The RASS is
a well validated and highly reliable 10-point scale, with scores
ranging from +1 to +4 assigned for levels of agitation up to
combativeness, and from −5 to −1 assigned for levels of
sedation.13
We observed that there was a significant positive cor-
relation between PAED score and RASS score with con-
founding factor of existence of disability. This observation
might indicate that the evaluation of a wide range of
sedative and agitated condition using RASS score at emer-
gence from anesthesia is useful to predict the occurrence
rate of severe agitation in the recovery phase. If we
observe predicted risk for occurrence of severe agitation
in the recovery phase, continuous higher attention should
be needed for these patients during the recovery phase
until discharge from hospital.
Clinical implication
Numerous clinical studies have shown that the emergence
agitation after sevoflurane anesthesia is a common phenom-
enon in pediatric patients. The typical manifestations of severe
emergence agitation are reportedly self-injury, including tilting
their bodies from the operation table, extending their necks to
avoid any medical equipment, and typical kicking behavior
while being emotionally inconsolable.26 It was also revealed
that the possible risk factors associated with emergence agita-
tion include younger age,27sleep disturbances in the preopera-
tive period due to the hostile environment, intolerance against
perceived postoperative pain, preoperative fear and anxiety,
use of short acting volatile anesthetic agents such as sevoflur-
ane or desflurane,28 and procedures in the oral-maxillofacial
region.29
It is well known that rapid emergence from general
anesthesia with dependable return of airway reflexes and cog-
nitive abilities are important minimum requirements following
general anesthesia. The use of sevoflurane as the sole anes-
thetic agent can speed awakening in pediatric patients under-
going dental treatment. Unfortunately, this rapid awakening is
accompanied by a high incidence of postanesthetic emergence
agitation.30
Most recently, we have reported that there was
a significant disturbance of sleep cycle after general
anesthesia in a disability patient who underwent dental
treatment, due to possible severe agitation after
anesthesia.31 Therefore, we should carefully manage the
behavioral condition of these pediatric patients during
perioperative periods estimated with useful score.
In conclusion, administration of a single dose of 0.1 mg/kg
midazolam 30 minutes before the completion of treatment in
extremely uncooperative pediatric patients undergoing dental
treatment under sevoflurane anesthesia significantly decreases
the incidence of severe emergence agitation at the emergence
after sevoflurane anesthesia, but not at the recovery phase.
Furthermore, the evaluation of sedative and agitation condition
using RASS score at emergence from anesthesia is a useful
method to predict the occurrence of severe agitation in the
recovery phase.
Dovepress Kawai et al
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